Optimization of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validation
Clinical and Experimental Immunology · 06.01.2026 · 220 (1)
DOI: 10.1093/cei/uxag032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 26.05.2026. Verfasst von Fahima Kausar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Leucid Bio Ltd., Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leucid Bio.
Abstract (Originalsprache)
Second-generation CAR T-cells have transformed the management of B-cell malignancy. However, in vivo functional persistence is often limited, highlighting a key mechanism of treatment failure. We have engineered a parallel (p)CAR platform that delivers dual CD28 and 4-1BB co-stimulation via a co-expressed CAR and chimeric co-stimulatory receptor (CCR). To target CD19, we employed an avidity-optimized FMC63 scFv to direct CAR specificity while utilizing an unmodified FMC63 scFv to target the CCR. Here, we describe the late-stage optimization of this system for Phase 1 clinical evaluation. First, we confirmed that the avidity-optimized scFv lacked off-target specificity. To minimize risk of insertional mutagenesis and immunogenicity, respectively, we transitioned from a gammaretrovirus to a third-generation lentiviral expression vector and removed epitope tags used to discriminate between CAR and CCR expression. Most strikingly, we found that inactivation of immune tyrosine activation motif 2 and 3 within our pCAR prototype markedly potentiated efficacy in xenograft-bearing NSG mice. Mechanistically, this resulted from increased pCAR T-cell functional persistence and organ infiltration, with enhanced local clearance of malignant B-cells. These data set the scene for evaluation of this iteratively honed pCAR candidate in a clinical trial in relapsed/refractory B-cell non-Hodgkin's lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leucid Bio Ltd., Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.
- King's College London, CAR Mechanics Group, Department of Precision & Population Oncology, School of Cancer and Pharmaceutical Sciences, London SE1 9RT, UK.
- King's College London, Department of Haematology, School of Cancer and Pharmaceutical Sciences, London SE5 9RS, UK.
- ViroCell Biologics, Zayed Centre for Research into Rare Diseases in Children, London WC1N 1DZ, UK.
- King's College Hospital, Department of Haematology, London SE5 9RS, UK.
- Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex BN21 2UD, UK.
ORCID-Profile: John Maher
Förderung
- Leucid Bio
Zitieren
APA
Kausar, F., Davis, C., Larcombe-Young, D., Bove, C., Farzaneh, F., Graham, C., Benjamin, R., Davies, D. M., & Maher, J. (2026). Optimization of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validation. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag032
Vancouver
Kausar F, Davis C, Larcombe-Young D, Bove C, Farzaneh F, Graham C, et al. Optimization of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validation. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag032
BibTeX
@article{Kausar2026,
author = {Kausar, Fahima and Davis, Christopher and Larcombe-Young, Daniel and Bove, Camilla and Farzaneh, Farzin and Graham, Charlotte and Benjamin, Reuben and Davies, David M and Maher, John},
title = {Optimization of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validation},
journal = {Clinical and Experimental Immunology},
year = {2026},
volume = {220},
number = {1},
doi = {10.1093/cei/uxag032}
}
EUVIMED